Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2018-02-28 Share Issue/Capital Cha…
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Antal aktier och röster i Medivir
Share Issue/Capital Change Classification · 99% confidence The document text explicitly discusses the 'Antal aktier och röster i Medivir' (Number of shares and votes in Medivir) following a recent new share issue ('nyemission'). It details the total number of shares (A and B classes) and the corresponding total votes as of the last trading day of the month. This content directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA), which covers announcements regarding new share issues or capital changes. It is not an earnings release, a proxy statement, or a general regulatory filing, but a specific capital structure update.
2018-02-28 Swedish
Annual Report 2017
Annual Report Classification · 100% confidence The document is a 'Bokslutskommuniké' (Year-end report) for Medivir AB for the period January-December 2017. It contains comprehensive financial summaries, management commentary, operational highlights, and detailed project status updates. As it covers a full fiscal year and includes substantive financial statements and analysis, it is classified as an Annual Report (10-K equivalent in this context). FY 2017
2018-02-14 Swedish
Audit Report / Information 2017
Audit Report / Information Classification · 98% confidence The document is explicitly titled "MEDIVIR AB – YEAR END REPORT JANUARY – DECEMBER 2017". It contains comprehensive financial summaries for the full year (January - December) and the fourth quarter (October - December), including detailed metrics like Net turnover, EBITDA, cash flow, and EPS. It also discusses significant events, pipeline progress, and includes a CEO's message. This structure is characteristic of a full annual financial report, which corresponds to the 10-K filing type in the US context, or its equivalent for non-US filers reporting full-year results. Since the definitions provided map the 'Official yearly report covering company activity and full financial performance' to '10-K', this is the most appropriate classification, despite the document being a 'Year End Report' rather than explicitly labeled '10-K'. The length (68,249 chars) confirms it is a full report, not a brief announcement (RPA/RNS). FY 2017
2018-02-14 English
Medivir has completed a directed share issue of approximately 155 MSEK
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing that Medivir AB has completed a 'directed issue' of new class B shares, raising approximately 155 MSEK. This action involves raising capital through the issuance of new shares, which directly relates to the company's capital structure and financing activities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). It is a specific announcement about a share issue, making 'CAP' the most precise classification over the general 'SHA' (Share Issue/Capital Change) or 'RPA' (Report Publication Announcement), as it details the outcome and purpose of the financing event itself.
2018-02-02 English
Medivir har genomfört en riktad nyemission om cirka 155 MSEK
Capital/Financing Update Classification · 98% confidence The document is a press release written in Swedish announcing that Medivir AB has completed a directed new share issue (riktad nyemission) raising approximately 155 MSEK. The text details the number of shares issued, the subscription price, the intended use of the net proceeds (accelerating clinical portfolio development), and the resulting increase in share capital and dilution. This activity directly relates to fundraising, financing activities, and changes in capital structure. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not an earnings release (ER), an annual report (10-K), or a general regulatory filing (RNS), as it describes a specific corporate finance action.
2018-02-02 Swedish
Medivir intends to make a directed share issue
Share Issue/Capital Change Classification · 98% confidence The document explicitly announces the 'intention to make a directed share issue' to qualified institutional investors, detailing the process (accelerated bookbuilding), the maximum number of shares (not exceeding 20%), and the intended use of proceeds (advancing clinical portfolio). This content directly relates to fundraising, capital structure changes, and the issuance of new shares. This aligns perfectly with the definition for Capital/Financing Update (CAP) or Share Issue/Capital Change (SHA). Since the core action is announcing the intent to issue new shares to raise capital, 'CAP' (Capital/Financing Update) is highly appropriate, as is 'SHA' (Share Issue/Capital Change). Given the focus on raising capital via a share issue, CAP is selected as the primary category, as it encompasses the financing aspect of the share issuance.
2018-02-01 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.